icon
Treatments
Programmeicon
How it works
Treatments, coaching and habit change programme
Coaching
The support of a dedicated health coach
Voy app
Track your progress whilst creating healthy sustainable habits
Results
About
Experts
Resourcesicon
Guides & tips
Tools and tips for lasting weight loss
Research & science
Evidence-based insights and clinical research
icon
icon
menu-close
OVERVIEW
Treatments
icon
How it works
icon
Coaching
icon
Voy app
icon
EXPLORE
Results
icon
About
icon
Experts
icon
Resources
icon
ACCOUNT
Login
icon
GET IN TOUCH
020 3912 9885
Mon-Fri 9:00-17:30
icon
Guides & tips
icon
Research & science
icon
Home/Guides & Tips/Medications/

Retatrutide, tirzepatide, or semaglutide?

Retatrutide, tirzepatide, or semaglutide? Comparing weight loss medications

Wondering how different weight loss medicines stack up? Here’s a head-to-head comparison of retatrutide vs tirzepatide vs semaglutide.

clinician image

Medically reviewed by

Dr Earim Chaudry (MBBS), Chief Medical Officer

iconPublished 4th June, 2025
Research-Based Comparison
Table of contents
  • What is retatrutide?
  • What is tirzepatide?
  • What is semaglutide?
  • Key differences between retatr...
  • Clinical data: semaglutide vs ...
  • Which medicine is better for w...
  • Ready to take the next step to...

Looking to try weight loss medication? There are a few options out there. For example, the weekly injections Wegovy and Mounjaro, which are brand names for semaglutide and tirzepatide, respectively. And in the next year or so, a new medicine called retatrutide is set to be available as well.

All of these medicines make you feel full by acting like your body’s natural hormones. But they each do that in their own way.

If you’re exploring which weight loss medication might be best for you, it’s important to understand the differences between them. We’ve got you—here’s a head-to-head comparison of retatrutide vs tirzepatide vs semaglutide.

What is retatrutide?

It’s a brand new weight loss medication that’s still being developed.

What sets retatrutide apart is that it mimics the behaviour of three hormones—GLP-1, GIP and GCG—rather than two (Mounjaro) or one (Wegovy). That’s why it’s sometimes given the nickname “triple G”. And this triple action suggests that it’s the most potent medicine of the lot.

Retatrutide is currently being investigated in clinical trials and isn’t due to be approved until at least mid-2026. But the results we have so far are impressive (more on that below!).

What is tirzepatide?

That would be the active ingredient in Mounjaro weight loss injections. It makes you feel full by bringing on the effects of the hunger hormones GLP-1 and GIP.

You might see Mounjaro being referred to as a GLP-1/GIP receptor agonist—which is just another way of describing how it works.

Mounjaro is approved in the UK as a treatment for weight loss and type 2 diabetes.

Discover Mounjaro
Feel like you’re doing everything right but still not hitting your health goals? Learn more about Mounjaro, an appetite-curbing medication that could help you lose up to 21% of your body weight.
icon
Science backed programme
icon
Personalised support
icon
Trusted by 100,000 customers across the UK

What is semaglutide?

And finally, we have semaglutide, the active ingredient in Wegovy and Ozempic.

These are two brand names for the same medicine. Semaglutide is called Ozempic when it’s used for type 2 diabetes (though Ozempic is sometimes prescribed off-label for weight) and Wegovy when it’s used for weight loss.

Semaglutide acts like just one hormone, GLP-1. But it still works very well! If you take it for over a year alongside healthy lifestyle changes, you could lose around 15% of your starting weight.

Key differences between retatrutide, tirzepatide and semaglutide

Okay, but how do these medicines compare? Let’s dive in. 

How they work

Semaglutide, tirzepatide and retatrutide are all separate medicines that work in their own way. To give you a quick recap:

  • Semaglutide acts like GLP-1
  • Tirzepatide acts like GLP-1 and GIP
  • Retatrutide acts like GLP-1, GIP and GCG

That means that they may all bring on different weight loss results (which is what the research shows).

Side effects

Because semaglutide and tirzepatide both act on the gut, they tend to bring on similar side effects. For both, the most common symptoms include nausea, constipation, vomiting, and diarrhoea.

How about tirzepatide and semaglutide vs retatrutide? There’s no official list of retatrutide side effects yet, because it isn’t approved. But it affects the gut, too. And in clinical research, the most commonly reported symptoms were the same as the above.

Side effects support at Voy

"If you're using Voy and you experience any side effects, rest assured that our expert clinicians are just a message or phone call away. They can adjust your dose, prescribe medication to ease your symptoms, or simply offer reassurance.

Everyone responds differently to weight loss treatment and we'll help you find what feels right for you."

Phoebe Fox - Weight Loss Specialist Clinician

Dosing

Though each of these medicines comes in different doses, they’re all weekly injections that are taken in a similar way.

For semaglutide and tirzepatide, you start on a low dose so that your body can adjust to the medicine, and then gradually move up to a higher strength every four weeks (provided that you aren’t getting any troublesome side effects).

It’s likely to be the same story for retatrutide, because that’s how it’s been taken in clinical trials.

Clinical data: semaglutide vs tirzepatide vs retatrutide

Now let’s take a look at weight loss results from clinical research. 

When it comes to tirzepatide vs retatrutide for weight loss, retatrutide appears to come out on top. We say “appears” because we have limited data.

But in a phase II trial, the average loss on retatrutide was 24.2% body weight after 48 weeks, while 26% of participants lost at least 30%. Whereas in another trial that lasted 88 weeks, the mean loss on Mounjaro was 25.3%.

What about retatrutide vs semaglutide? Retatrutide seems to win again. After 68 weeks on Wegovy injections, the average loss is 14.9%.

So, out of the medicines you can get right now, Mounjaro has been shown to drive the most weight loss. But research suggests that retatrutide may be even more effective.

Which medicine is better for weight loss?

We’re asked this question a lot here at Voy. And it’s a tough one, because everyone can respond differently to medicines.

What’s most suitable for you depends on a bunch of factors, including your current health, medical history and your health goals. It also depends if you’ve tried weight loss medication before and whether you experienced side effects. Your provider will weigh all of that up when deciding which medicine to prescribe you.

This also feels like a good time to remind you that retatrutide isn’t approved yet, which means that a clinician can’t prescribe it to you. At the earliest, it might be available in mid-2026.

Ready to take the next step towards your health goals?

When combined with a healthy lifestyle, weight loss medication can be a gamechanger for some people. They can be a great option if you’ve tried to lose weight another way but didn’t see the results you hoped for.

You can get Mounjaro or Wegovy weight loss injections through our weight loss programme, plus dedicated support from our clinicians and coaches. We use a structured habit-change approach that’s backed by science and designed to transform your lifestyle.

Want to try it out? Take our short quiz to see if you’re eligible. Our clinicians will review and come back to you within minutes.

Looking to start you weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
FAQ

Retatrutide vs tirzepatide vs semaglutide: FAQs

Dr Earim Chaudry, MBBS
DisclaimerAt Voy, we ensure that everything you read in our blog is medically reviewed and approved. However, the information provided is not meant to replace professional medical advice, diagnosis, or treatment. It should not be relied upon for specific medical advice.
References
icon¹

Aronne, Louis J, et al. “Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: the SURMOUNT-4 Randomised Clinical Trial.” JAMA,scribble-underline vol. 331, no. 1, 2024:38-48. https://jamanetwork.com/journals/jama/fullarticle/2812936.

icon²

Jastreboff, Ania M., et al. “Triple-hormone-receptor Agonist Retatrutide For Obesity—A Phase 2 Trial.” The New England Journal of Medicinescribble-underline, vol. 389, no. 6, 2023:514-526 www.nejm.org/doi/full/10.1056/NEJMoa2301972.

icon³

“Mounjaro: Information For The Patient.” Electronic Medicines Compendium.scribble-underline www.medicines.org.uk/emc/files/pil.15481.pdf. Accessed 23 May 2025.

icon⁴

“Wegovy: Information For The Patient.” Electronic Medicines Compendiumscribble-underline. www.medicines.org.uk/emc/files/pil.13800.pdf. Accessed 23 May 2025.

icon⁵

Wilding, John P.H., et al. “Once-weekly Semaglutide In Adults With Overweight Or Obesity.” The New England Journal of Medicinescribble-underline, vol. 384, no. 11, 2021:989-1002 www.nejm.org/doi/full/10.1056/NEJMoa2032183.

card-image
Medication
Retatrutide dosage guide
Retatrutide, a weekly weight loss injection, isn’t approved yet, but here’s what we know right now about the dosing schedule for this experimental treatment.
card-image
Medication
How tirzepatide works
Tirzepatide is the active ingredient in Mounjaro weight loss injections. Here’s how it works to drive powerful results.
card-image
Medication
Amycretin for weight loss
Here’s what we know so far about Amycretin, an experimental weight loss tablet.
card-image
Medication
Retatrutide for weight loss treatment
Retatrutide is an experimental weight loss treatment. Here’s what clinical research currently shows about how effective it is.
Have a question?
Whatever it is, get in touch:
message
020 3912 9885Mon-Fri 9:00-17:00
message
help@joinvoy.comWe aim to reply in 24hrs
Mon-Fri 9:00-17:00
We aim to reply in 24hrs
Our services are not intended for use in a medical emergency. If you need urgent medical attention, please call 111 or 999

PROGRAMME

  • How it works
  • Treatments
  • Coaching
  • The Voy app

VOY

  • Results
  • About
  • Our medical experts

HELP

  • Help Centre (FAQ)
logo
Privacy PolicyTerms & Conditions
Terms of SaleComplaints
Pharmacies: Manual Pharmacy
Superintendent Pharmacist
Vinisha Kanda
GPhC Registration: 2203475
Copyright 2025 Voy™. All rights reserved.
cards
pharmacy-contact
Privacy Preference Center
We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below. The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. We also use third-party cookies that help us analyse how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. These cookies will only be stored in your browser with your prior consent. You can choose to enable or disable some or all of these cookies but disabling some of them may affect your browsing experience.
Manage Consent Preferences
icon
Necessary Cookies
Always Active
Necessary cookies ensure the basic functionalities of the website, such as security, network management, and accessibility. These cookies cannot be disabled and do not store personal information.
icon
Preferences Cookies
Preferences cookies allow the website to remember information that changes the way the site behaves or looks, such as your preferred language or region.
icon
Statistics Cookies
Statistics cookies help us understand how visitors interact with the website by collecting and reporting information anonymously. These cookies provide insights into metrics such as page visits and traffic sources.
icon
Marketing Cookies
Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and more valuable to publishers and third-party advertisers.